Aug. 5, 2013
Shenogen Pharma of Beijing raised $20 million in a series C funding round, which the company will use to support a Phase II trial of its lead drug candidate, icaritin - a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. The investors also received warrants to buy an additional $10 million in shares.